4.6 Article

Early effects of Aβ1-42 oligomers injection in mice: Involvement of PI3K/Akt/GSK3 and MAPK/ERK1/2 pathways

Journal

BEHAVIOURAL BRAIN RESEARCH
Volume 314, Issue -, Pages 106-115

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbr.2016.08.002

Keywords

Beta-amyloid; Cognitive impairment; Oxidative stress; Akt; ERK1/2; GSK3

Funding

  1. Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)
  2. FIRB Accordi di programma [RBAP11HSZS]
  3. PRIN [2010PWNJXK_002]
  4. Fondazione del Monte di Bologna e Ravenna

Ask authors/readers for more resources

Neuronal and synaptic loss are the best pathological correlates for memory decline in Alzheimer's disease (AD). Soluble beta-amyloid oligomers (A beta O) are considered to putatively play a crucial role in the early synapse loss and cognitive impairment observed in AD. Evidence suggests that oxidative stress and apoptosis are involved in the mechanism of A beta-induced neurotoxicity and AD pathogenesis. This study aimed to explore the molecular mechanisms that contribute to the early memory deficits induced by intracerebroventricular injection of A beta O in mice. Ten days after a single A beta O injection memory impairments were observed, as measured by Morris water maze and novel object recognition tests. Cognitive decline was associated with increased oxidative stress, caspase-9 activation, and decreased hippocampal synaptophysin immunoreactivity. Furthermore, GSH levels were significantly higher in A beta O-injected mice than in sham mice, showing that a protective mechanism might develop due to oxidative stress. Additionally, A beta O-induced toxicity was aligned with an increment of the activation of Akt and ERK1/2, and reduced activity of GSK3. These findings suggest that A beta O injection triggers a cascade of events that mimic the key neuropathological hallmarks of AD. A beta acute injection helps to better understand how this peptide impairs specific signaling pathways leading to synaptic and memory dysfunctions. Thus, this model is a valid tool for investigating AD and may suggest a new way to develop neuroprotective therapies at such early stages of the disease. (C) 2016 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available